Schedule 13G ownership disclosure

CytomX Therapeutics Inc

Common Stock, $0.00001 par value per share · CUSIP: 23284F105

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Venrock Healthcare Capital Partners III, L.P.

    Shares: 15,561,500.00 · Class: 9.4%

  • VHCP Co-Investment Holdings III, LLC

    Shares: 15,561,500.00 · Class: 9.4%

  • Venrock Healthcare Capital Partners EG, L.P.

    Shares: 15,561,500.00 · Class: 9.4%

  • VHCP Management III, LLC

    Shares: 15,561,500.00 · Class: 9.4%

  • VHCP Management EG, LLC

    Shares: 15,561,500.00 · Class: 9.4%

  • Nimish Shah

    Shares: 15,561,500.00 · Class: 9.4%

  • Bong Y. Koh

    Shares: 15,561,500.00 · Class: 9.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001738048-25-000016
Form type
SCHEDULE 13G/A
Filer
CytomX Therapeutics, Inc.
CIK
CIK 1501989
Filed
Nov 14, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub